

BULLETIN

Blue Cross and Blue Shield of Minnesota
and Blue Plus

March 14, 2008

April 2008 HCPCS code update

Effective with dates of service on or after April 1, 2008, Blue Cross and Blue Shield of Minnesota and Blue Plus will accept quarterly Level II (alphanumeric) HCPCS* additions and revisions published by the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA).

Submitting new codes

Blue Cross will accept all added and revised HCPCS Level II procedure codes for dates of service April 1, 2008 and later. Claims submitted with new or revised procedure codes with a date of service before April 1, 2008 will be denied or rejected.

Code list

HCPCS and CPT® codes are generally only published once a year; however, CMS or AMA may publish added, revised and/or deleted codes on a quarterly basis. Following is a list of the added and revised codes.

ADDED CODES (all codes listed below are effective for dates of service April 1, 2008 and later unless otherwise specified)

J7611	Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1 mg
J7612	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg
J7613	Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg
J7614	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg
K0672	Addition to lower extremity orthosis, removable soft interface, all components, replacement only, each
Q4096	Injection, Von Willebrand factor complex, human, ristocetin cofactor (not otherwise specified), per i.u. VWF:RCO
Q4097	Injection, Immune globulin (Privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
Q4098	Injection, Iron dextran, 50 mg
Q4099	Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms
S3628	Placental alpha microglobulin-1 rapid immunoassay for detection of rupture of fetal membranes
90650	Human Papillomavirus (HPV) vaccine, types 16 and 18, bivalent, 3 dose schedule, for intramuscular use Effective January 1, 2008
90681	Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use <i>Effective January 1, 2008</i>
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 years through 6 years of age, for intramuscular use <i>Effective January 1, 2008</i>
3340F	Mammogram assessment category of "incomplete: additional imaging evaluation" documented (RAD) ⁵
3341F	Mammogram assessment category of "negative" documented (RAD) ⁵
3342F	Mammogram assessment category of "benign" documented (RAD) ⁵
3343F	Mammogram assessment category of "probably benign" documented (RAD) ⁵
3344F	Mammogram assessment category of "suspicious" documented (RAD) ⁵
3345F	Mammogram assessment category of "highly suggestive of malignancy" documented (RAD) ⁵
3350F	Mammogram assessment category of "known biopsy proven malignancy" documented (RAD) ⁵

Continued on back



REVISED CODE (effective for dates of service April 1, 2008 and later)

KT	Beneficiary resides in a competitive bidding area and travels <u>outside that</u> to a non- competitive bidding area and receives a <u>competitive bid item</u> from a non-contract supplier
----	--

Questions?

If you have any questions, please contact provider service at (651) 662-5200 or toll free at 1-800-262-0820.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association.

HCPCS* stands for Health Care Procedure Coding System